Summary
A bioRxiv preprint reports using six-base sequencing to analyse DNA modifications in cell-free DNA released by neural cells into cerebrospinal fluid. The authors say the approach could support liquid-biopsy research into neurodegenerative disease.
Researchers have reported using six-base sequencing to profile DNA modifications in cell-free DNA released from neural cells into cerebrospinal fluid (CSF). In a bioRxiv preprint posted on September 13, 2026, the team says the method can produce molecular, quantitative and qualitative information about biological processes associated with neurodegeneration.
The work is a research-stage advance in neurological liquid biopsy: analysing biological material in a body fluid instead of relying only on a tissue sample. The authors describe the approach as a way to study neurological conditions and develop soluble biomarkers, while emphasising that access to the brain’s target tissue is limited.
Why cerebrospinal fluid is useful
CSF is the fluid surrounding the brain and spinal cord. It can contain molecules and fragments released by cells in the nervous system, including cell-free DNA. Cell-free DNA consists of DNA fragments circulating outside cells; its sequence and chemical modifications can provide information about the cells from which it originated and the biological processes affecting them.
The preprint focuses on six-base sequencing, a sequencing strategy designed to capture DNA modification information alongside the underlying DNA sequence. That added molecular layer is important because two DNA fragments can have the same sequence while carrying different chemical marks. Profiling those marks may provide information that sequence-only analysis would miss.
What the preprint reports
The authors say their strategy profiles DNA modifications in neural-cell-derived cell-free DNA from CSF and provides both quantitative and qualitative molecular insights into ongoing neurodegenerative biology. They present this as a foundation for liquid-biopsy approaches to neurological conditions, rather than as an established clinical test.
The supplied abstract describes the sequencing approach and its intended biological use. It does not provide a study population, sample size, comparator, diagnostic-accuracy estimate or patient outcome in the record available here. Those study details will be important for determining how the method performs across specific neurological diseases and whether its molecular signals can support diagnosis, monitoring or treatment research.
The evidence is currently a bioRxiv preprint and has not been presented here as a completed clinical validation study. The paper also discloses that several authors are employees of biomodal limited and hold share options, a relevant relationship because the work concerns a sequencing technology.
If validated in defined patient cohorts, the approach could help researchers examine molecular changes in the nervous system using CSF samples and identify candidate biomarkers for further study. Its immediate contribution is the reported ability to combine cell-free DNA analysis with DNA-modification profiling in material released by neural cells.